{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:55Z","timestamp":1792896955057,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":855,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1111\/jth.14838","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T04:38:54Z","timestamp":1586925534000},"page":"1637-1647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Evaluation of andexanet alfa and four\u2010factor prothrombin complex concentrate (4F\u2010PCC) for reversal of rivaroxaban\u2010 and apixaban\u2010associated intracranial hemorrhages"],"prefix":"10.1016","volume":"18","author":[{"given":"Megan E.","family":"Barra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin S.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P.","family":"Rosovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Fuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14838_bb0010","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants amont nonvalvular atrial fibrillation patients: the Aristophanes study","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1111\/jth.14838_bb0015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","article-title":"Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta\u2010analysis","volume":"134","author":"Gomez\u2010Outes","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14838_bb0020","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta\u2010analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1111\/jth.14838_bb0025","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant\u2010associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"10.1111\/jth.14838_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Zerfoss CL. Guideline for reversal of antithrombotics in intracranial hemorrahge","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"10.1111\/jth.14838_bb0035","unstructured":"Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies; 2011."},{"key":"10.1111\/jth.14838_bb0040","unstructured":"Eliquis (apixaban) [package insert]. New York, NY: Bristol\u2010Myers Squibb Company and Pfizer Inc; 2019."},{"key":"10.1111\/jth.14838_bb0045","unstructured":"Andexxa (coagulation factor Xa (recombinant), inactivated\u2010zhzo) [package insert]. Portola Pharmaceuticals, Inc; 2018."},{"key":"10.1111\/jth.14838_bb0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14838_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12245-018-0215-6","article-title":"The impact of prothrombin complex concentrates when treating DOAC\u2010associated bleeding: a review","volume":"11","author":"Hoffman","year":"2018","journal-title":"Int J Emerg Med"},{"key":"10.1111\/jth.14838_bb0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic reivew and meta\u2010analysis","volume":"116","author":"Chai\u2010Adisaksopha","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14838_bb0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor xa inhibitor\u2010related major bleeding with prothrombin complex concentrate: a meta\u2010analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"10.1111\/jth.14838_bb0070","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo\u2010controlled, crossover study in health subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.14838_bb0075","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban\u2010 or apixaban\u2010associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14838_bb0080","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrates for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Shulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14838_bb0085","first-page":"1","article-title":"A low\u2010dose 4f\u2010pcc protocol for DOAC\u2010associated intracranial hemorrhage","author":"Berger","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1111\/jth.14838_bb0090","first-page":"726","article-title":"Reversal of oral anticoagulants for intracerebral hemorrahge patients: best strategies","volume":"38","author":"Fuh","year":"2017","journal-title":"Semin Respir Cir Care Med"},{"key":"10.1111\/jth.14838_bb0095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four\u2010factor prothrombin complex concentrate (4F\u2010PCC) in patients with factor Xa inhibitor\u2010related bleeding: a retrospective study","volume":"48","author":"Smith","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1111\/jth.14838_bb0100","first-page":"1","article-title":"Utilization of 4\u2010factor prothrombin complex concentrate for reversal of oral factor Xa inhibitor\u2010associated acute major bleeding: a case series","volume":"59","author":"Reynolds","year":"2020","journal-title":"J Pharm Pract"},{"issue":"6","key":"10.1111\/jth.14838_bb0105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.wneu.2015.08.042","article-title":"Administration of 4\u2010factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors","volume":"84","author":"Grandhi","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1111\/jth.14838_bb0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.wneu.2015.11.086","article-title":"New target\u2010specific oral anticoagulants and intracranial bleeding: management and outcome in a single\u2010center case series","volume":"88","author":"Senger","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1111\/jth.14838_bb0115","article-title":"Evaluation of the use of low\u2010dose\u20104\u2010factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients","author":"Allison","year":"2018","journal-title":"J Intensive Care Med"},{"key":"10.1111\/jth.14838_bb0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non\u2010vitamin K antagonist oral anticoagulant\u2010related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1111\/jth.14838_bb0125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Study Investigators. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: A prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14838_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4\u2010factor prothrombin complex concentrate (4F\u2010PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"key":"10.1111\/jth.14838_bb0135","first-page":"382","article-title":"Clinical experience reversing factor Xa inhibitors with four\u2010factor prothrombin complex concentrate in a community hospital","volume":"16","author":"Tellor","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.14838_bb0140","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ajem.2019.01.008","article-title":"Four\u2010factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage","volume":"37","author":"Dybdahl","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1111\/jth.14838_bb0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11739-018-1977-9","article-title":"Treatment of apixaban\u2010 and rivaroxaban\u2010associated major bleeding using 4\u2010factor prothrombin complex concentrate","volume":"14","author":"Sheikh\u2010Taha","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1111\/jth.14838_bb0150","first-page":"1","article-title":"Four\u2010factor prothrombin complex concentrate for the reversal of direct oral anticoagulants","author":"Zada","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1111\/jth.14838_bb0155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.chest.2019.02.335","article-title":"Prothrombin complex concentrate or coagulation factor Xa (recombinant), inactivated zhzo","volume":"155","author":"Peled","year":"2019","journal-title":"Chest"},{"key":"10.1111\/jth.14838_bb0160","first-page":"1","article-title":"Key points to consider when evaluating andexxa for formulary addition","author":"Peled","year":"2019","journal-title":"Neurocrit Care"},{"key":"10.1111\/jth.14838_bb0165","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14838_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrahge","volume":"49","author":"Frontera","year":"2020","journal-title":"J Throm Thrombolys"},{"key":"10.1111\/jth.14838_bb0175","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1111\/jth.14838_bb0180","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamaneurol.2016.2619","article-title":"Association of key magnetic resonance imaging markers of cerebral small vessel disease with hematoma volume and expansion in patients with lobar and deep intracerebral hemorrahge","volume":"73","author":"Boulouis","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1111\/jth.14838_bb0185","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/STROKEAHA.109.554667","article-title":"Systemic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrahge identifies patients at highest risk for hematoma expansion: the spot sign score","volume":"40","author":"Delgado Almandoz","year":"2009","journal-title":"Stroke"},{"key":"10.1111\/jth.14838_bb0190","unstructured":"Prothrombin complex concentrates (human) [(factors II, VII, IX, X), protein C, and protein S]. Wolters Kluwer Clinical Drug Information, Inc. (Lexi\u2010Drugs). Wolters Kluwer Clinical Drug Information, Inc.; April 15, 2013."},{"key":"10.1111\/jth.14838_bb0195","unstructured":"Alfa Andexanet. Wolters Kluwer Clinical Drug Information, Inc. (Lexi\u2010Drugs). Wolters Kluwer Clinical Drug Information, Inc.; April 15, 2013."},{"key":"10.1111\/jth.14838_bb0200","unstructured":"Kcentra (prothrombin complex concentrate (human)) [package insert]. Kankakee, IL. CSL Behring LLC; 2018."},{"key":"10.1111\/jth.14838_bb0205","doi-asserted-by":"crossref","first-page":"849","DOI":"10.5811\/westjem.2018.6.37932","article-title":"Impact of a pharmacist\u2010driven prothrombin complex concentrate protocol on time to administration in patients with warfarin\u2010associated intracranial hemorrhage","volume":"19","author":"Corio","year":"2018","journal-title":"West J Emerg Med"},{"key":"10.1111\/jth.14838_bb0210","series-title":"General chapter <797> Pharmaceutical Compounding\u2014Sterile Preparations","year":"2017"},{"key":"10.1111\/jth.14838_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12028-019-00740-5","article-title":"Independent validation of the hematoma expansion prediction score: a non\u2010contrast score equivalent in accuracy to the spot sign","volume":"31","author":"Yogendrakumar","year":"2019","journal-title":"Neurocrit Care"},{"key":"10.1111\/jth.14838_bb0220","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1002\/ajh.25326","article-title":"Andexanet alfa\u2010 the first 150 days","volume":"94","author":"Culbreth","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14838_bb0225","first-page":"1","article-title":"Real\u2010world utilization of andexanet alfa","author":"Brown","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1111\/jth.14838_bb0230","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.STR.0000258078.35316.30","article-title":"Determinants of intracerebral hemorrahge growth: an exploratory analysis","volume":"38","author":"Broderick","year":"2007","journal-title":"Stroke"},{"key":"10.1111\/jth.14838_bb0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1747-4949.2010.00563.x","article-title":"Small intracerebral hemorrhages are associated with less haematoma expansion and better outcomes","volume":"6","author":"Dowlatshahi","year":"2011","journal-title":"Int J Stroke"},{"key":"10.1111\/jth.14838_bb0240","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1111\/jth.14838_bb0245","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622013411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622013411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:28:46Z","timestamp":1761535726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622013411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1538783622013411"],"URL":"https:\/\/doi.org\/10.1111\/jth.14838","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of andexanet alfa and four\u2010factor prothrombin complex concentrate (4F\u2010PCC) for reversal of rivaroxaban\u2010 and apixaban\u2010associated intracranial hemorrhages","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}